Cause-specific mortality in Scottish patients with colorectal cancer with and without type 2 diabetes (2000–2007)

Abstract

Aims/hypothesis The objective of this study was to use Scottish national data to assess the influence of type 2 diabetes on (1) survival (overall and cause-specific) in multiple time intervals after diagnosis of colorectal cancer and (2) cause of death. Methods Data from the Scottish Cancer Registry were linked to data from a population-based national diabetes register. All people in Scotland diagnosed with nonmetastatic cancer of the colon or rectum in 2000-2007 were included. The effect of pre-existing type 2 diabetes on survival over four discrete time intervals (<1, 1-2, 3-5 and >5 years) after cancer diagnosis was assessed by Cox regression. Cumulative incidence functions were calculated representing the respective probabilities of death from the competing causes of colorectal cancer, cardiovascular disease, other cancers and any other cause. Results Data were available for 19,505 people with colon or rectal cancer (1,957 with pre-existing diabetes). Causespecific mortality analyses identified a stronger association between diabetes and cardiovascular disease mortality than that between diabetes and cancer mortality. Beyond 5 years after colon cancer diagnosis, diabetes was associated with a detrimental effect on all-cause mortality after adjustment

The relationship between diabetes and colorectal cancer prognosis: A meta-analysis based on the cohort studies

“…In our meta-analysis, year of publication ranged from 2003 to 2016, and the regions included 2 American countries[7, 13–15, 18, 19, 27, 30, 33, 37, 41, 42, 45, 46], 6 European countries[6, 11, 17, 28, 32, 39, 40, 44], 2 Asian countries[8, 9, 12, 16, 20, 29, 34–36, 38, 43, 47] and 1 Oceania country[31]; the included studies contained 15 retrospective[9, 10, 14, 16–20, 27, 33, 36, 37, 39, 41, 47] and 21 prospective[6–8, 11–13, 15, 28–32, 34, 35, 38, 40, 42–46] cohort studies; the sample size ranged from 391 to 1056243, and the mean age of study ranged from 46.4 to 72.07. In DM ascertainment, 25 studies[6, 8, 9, 11–15, 18, 19, …”

“…In DM ascertainment, 25 studies[6, 8, 9, 11–15, 18, 19, 28, 29, 31, 33–37, 39–42, 44–46] used the method of medical records, 5 studies[16, 20, 38, 43, 47] used the method of blood sugar test, and 6 studies[7, 10, 17, 27, 30, 32] used the method of self-reported. To avoid the effects of confounders, we preferred to extract the adjusted outcome effect estimates, but we still found that the outcome effect estimates of 4 studies were not adjusted.…”

“…The number of studies on the rectal cancer data provided was 10[6, 8, 10, 11, 13, 28, 40, 44, 45], there was only one study on CVDS, DFS and RFS, the pooled HRs on CVDS, DFS or RFS were not analyzed. The pooled HR on OS was statistically significant (HR on OS: 1.16, 95%CI: 1.04–1.29), the pooled HR indicated that there were no significant difference on CSS.…”

“…A meta-analysis has reported the effect of DM on CRC prognosis[5], but since 2013, a series of large-scale long-term cohort studies had comprehensively reported the outcome effect estimates on the relationship between DM and CRC prognosis, and their results were still consistent[6–20]. For example, in overall survival (OS) of CRC, several studies found that DM showed a significant decreased risk in OS[6, 7, 12–14, 17], and others found no link[8–11, 15, 16, 18–20]. The data from these studies has also allowed us to evaluate the relationship between DM and CRC prognosis more accurately.…”

Expression Characteristics of Proteins of the Insulin-like Growth Factor Axis in Non-small Cell Lung Cancer Patients with Preexisting Type 2 Diabetes Mellitus

“…Accumulating epidemiologic evidence suggests that type 2 diabetes mellitus (T2DM) and/or certain diabetes treatments may be associated with prevalence, progression, or prognosis of some malignancies, but the risk may vary according to diabetes therapy and cancer site (Barone et al, 2008;Currie et al, 2012;Wang et al, 2013). For example, the cohorts of patients with T2DM were reported to have increased prevalence in several types of malignancies, such as liver, colorectal, pancreas, endometrial and breast cancers, etc (He et al, 2010;Wang et al, 2012;Elena et al, 2013;Zhang et al, 2013), and the all-cause mortality in patients with preexisting T2DM (preDM) was also increased in those with breast, prostate, pancreas and colorectal cancer, etc (Arif, et al, 2011;Currie et al, 2012;Hwang et al, 2013;Walker et al, 2013). Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide (Siegel et al, 2013).…”